Cognition Therapeutics Reports Financial Results for the First Quarter 2026 and Provides Business Update
Cognition Therapeutics confirmed that the FDA Division of Psychiatry has accepted its meeting request for May 20, 2026, to discuss registrational plans for zervimesine in DLB psychosis. The company reported Q1 cash and equivalents of $31.2 million, plus $25.6 million in grant funds, sufficient to fund operations into the second quarter of 2027.
Key figures
- Revenue
- 3979000
- Net loss
- 4570000
- Cash runway
- Q2 2027
- Cash position
- 31225000
- G and a expenses
- 2697000
- R and d expenses
- 6120000
- Grant funds remaining
- 25600000
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.